Mood Disorders

A groundbreaking study links antibiotic exposure to increased depression risk in adolescents, highlighting urinary analysis as a potential screening tool.

GLP-1 receptor agonists emerge as potential game-changers in psychiatric treatment, targeting mental disorders and improving cognitive function.

Roger S. McIntyre, MD, FRCPC, shares the backstory and pharmacology of incretins to better understand the role of GLP-1 RAs in psychiatry.

NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD.

New research reveals the complex relationship between ADHD and bipolar disorder, highlighting genetic overlaps and treatment considerations for effective management.

Given that individual differences exist regarding the effects of brain injury and gaps persist in the treatment continuum, challenges arise in treating individuals with acquired brain injury. Addressing these challenges can improve patient outcomes.

How should clinicians approach treatment when their patient disagrees with the diagnosis?

Here are 10 things to consider when treating a patient with mood disorders.

Learn more about the latest research on bipolar disorder, including the impacts of childhood trauma on its development and the correlation between bipolar disorder and cardiovascular risk.

Bipolar disorder is both underdiagnosed and overdiagnosed—though missing the diagnosis is more common. Check out this update from David N. Osser, MD.

Check out these top 10 best practices for treating patients with mood disorders.

The presentation of catatonia can vary, making its management challenging, particularly in resource-limited settings in South Africa.

A systematic review and meta-analysis showed moderate-quality evidence supporting lithium’s ability to lower mortality rates.

Learn more about a specific subset of mood disorders.

A new collaboration to address sleep disturbances associated with cognitive impairment, an unmet need.

A refined rTMS protocol, the Stanford Accelerated Intelligent Neuromodulation Therapy for major depressive disorder, shows promise in bipolar disorder.

The context and timing of symptoms is critical for a timely and accurate bipolar diagnosis.

SSRI and SNRI antidepressants were deemed the safest classes of antidepressants in the event of excess dosing in an assessment of 14 antidepressants prescribed in the United States on 3 safety indices.

Studies report an increased risk for suicidal thoughts, suicide attempts, and even death by suicide following brain injury.

Perinatal mood and anxiety disorders affect 1 in 5 of perinatal individuals who are pregnant or up to 1 year postpartum. Over the past 2 decades, the US has seen an alarming rise in these disorders.

Research shows an increased risk for suicidal thoughts, suicide attempts, and even death by suicide following brain injury.

The weight-adjusted waist index was a stronger predictor of depressive symptoms than either body mass index or waist circumference.

Review tapering challenges and strategies for benzodiazepines in this Special Report article.

The latest in mood disorder news, all in one place.

Antidepressants are differentiated by long-term response in a 2-year cohort study of patients with MDD.

“The selectivity of NBI-1070770 for the NMDA NR2B receptor may benefit patients with moderate to severe depression.”

The experts weighed in on a wide variety of psychiatric issues for the March 2024 issue of Psychiatric Times.

From a promising new intervention for treatment-resistant depression to another look at the STAR*D controversy, here are highlights from the week in Psychiatric Times.

Our Mood Disorders Section Editor discusses the disorder in honor of World Bipolar Day.

What is new in research on bipolar disorder?